Robbi sells MS 31.6: Synthetic Biologics (SYN): Lead Investigator to Present New Data on Trimesta
Inc. (NYSE: SYN) announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating Trimestaâ¢, the Company's oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), is scheduled to ... ...
41 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home